Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7775544 | 0.90 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1SMN1; SMN2CCR6PAX8 | |
| SCHEMBL24394500 | 0.89 | L3MBTL1 (0.50) | L3MBTL1ITGB3ITGA2BALDH1A1CCR6 | |
| SCHEMBL23807836 | 0.89 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1LMNASMN1; SMN2HTR2C | |
| SCHEMBL21997180 | 0.88 | LMNA (0.55) | L3MBTL1LMNASMN1; SMN2TGM2SYK | |
| SCHEMBL23807837 | 0.86 | L3MBTL1 (0.47) | L3MBTL1LMNASMN1; SMN2CCR6PAX8 | |
| SCHEMBL31218933 | 0.84 | L3MBTL1 (0.50) | L3MBTL1HTR2CSLC6A4 | |
| SCHEMBL25211503 | 0.84 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1LMNAHTR2CSLC6A4 | |
| SCHEMBL16466428 | 0.84 | L3MBTL1 (0.46) | L3MBTL1ITGB3ITGA2BALDH1A1CCR6 | |
| SCHEMBL10308981 | 0.83 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1SMN1; SMN2CCR6PAX8 | |
| SCHEMBL16993182 | 0.83 | L3MBTL1 (0.62) | L3MBTL1ALDH1A1LMNAHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885ITGB3 3396/4885ITGA2B 3218/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885ITGB3 3396/4885ITGA2B 3218/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885ITGB3 3396/4885ITGA2B 3218/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885ITGB3 3396/4885ITGA2B 3218/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885ITGB3 3396/4885ITGA2B 3218/4885 |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885ITGB3 3396/4885ITGA2B 3218/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885ITGB3 3396/4885ITGA2B 3218/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885ITGB3 3396/4885ITGA2B 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.